<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766025</url>
  </required_header>
  <id_info>
    <org_study_id>D3560C00059</org_study_id>
    <secondary_id>Rosuvastatin Calcium</secondary_id>
    <nct_id>NCT00766025</nct_id>
  </id_info>
  <brief_title>Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin</brief_title>
  <official_title>A Phase I, Open Label, Parallel Group, Single and Multiple Dose Study in Taiwanese Subjects Identified as CYP2C19 Poor Metabolizers or Extensive Metabolizers Receiving 20 Milligrams of Rosuvastatin Calcium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine Taiwanese subjects identified as CYP2C19 poor
      and extensive metabolizers while taking single and multiple dosing a rosuvastatin calcium.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels of rosuvastatin in Taiwanese subjects identified as CYP2CIP poor and extensive metabolizers</measure>
    <time_frame>Scheduled times during the 18 days that the study drug is taken</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood levels for assessment of pharmacodynamic (lipid) parameters</measure>
    <time_frame>Days -1 and 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rosuvastatin in Taiwanese subjects identified as CYP2C19 poor and extensive metabolizers</measure>
    <time_frame>Screening through completion of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CYP2C19 Poor</condition>
  <condition>Extensive Metabolizers</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin Calcium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin Calcium</intervention_name>
    <description>single oral dose on days 1, 4, 5, 6, 10-16, 17</description>
    <arm_group_label>Rosuvastatin Calcium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have blood drawn for genotyping (determination of EM or PM of CYP2C19,
             determination of OATP-C1B1, BCRP 421C&gt;A, and CYP2C9.

          -  Males and females aged 20-65, inclusive

          -  Women who are surgically sterilized, post-menopausal for at least one year, or not
             pregnant and/or lactating. Women of childbearing potential must be willing to abstain
             from sexual activity or use an effective contraception as outlined in protocol.

        Exclusion Criteria:

          -  Subjects with deoxyribonucleic acid (DNA) that codes for OATP-C 1B1 *5 and *15, BCRP
             421C&gt;A and/or non wild-type CYP2C9

          -  History of adverse drug reaction or hypersensitivity to statins or drugs with a
             similar chemical structure to rosuvastatin

          -  History or presence of gastrointestinal, hepatic, or renal disease or other conditions
             known to interfere with absorption, distribution, metabolism and excretion (ADME) of
             drugs

          -  Any contraindication determined by review of a detailed medical and drug history,
             complete physical examination, vital signs, blood chemistry, hematology, and
             electrocardiogram (ECG)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Regeio Mosquea-Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Meng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tzung-Dau Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2008</study_first_submitted>
  <study_first_submitted_qc>October 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <last_update_submitted>February 27, 2009</last_update_submitted>
  <last_update_submitted_qc>February 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Cressman, Medical Science Executive Director, Clinical Development, Cardiovascular</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Taiwanese Subjects</keyword>
  <keyword>CYP2C19</keyword>
  <keyword>Poor Metabolizers</keyword>
  <keyword>Extensive Metabolizers</keyword>
  <keyword>Taiwanese Subjects identified as CYP2C19 Poor or Extensive Metabolizers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

